RNS Number : 8336T
OptiBiotix Health PLC
20 January 2025

OptiBiotix Health plc
("OptiBiotix"or the"Company")

Launch of products on Amazon India

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces the launch of multiple SlimBiome® containing products under OptiBiotix's GoFigure® brand on Amazon India.

India is already the most populous nation on Earth, anticipated to have the world's largest cohort of medium to high level income consumers by 2035. With obesity prevalence currently measured at 40.3%, India represents a huge area of opportunity for weight management products.

OptiBiotix's wholly owned subsidiary, OptiBiotix India, will sell GoFigure®products via Amazon and continue to sell in store through Apollo Pharmacies and Apollo's own website across India as part of a multi-channel approach. Launching meal replacement and flavoured shots on Amazon India is part of a planned strategy to invest in high growth markets and increase final product sales to customers through ecommerce channels. This multichannel approach complements our core business-to-business activities by raising the awareness of SlimBiome® containing products across multiple channels and partners.

The Amazon India launch has coincided with a rebrand of packaging and relaunch with Apollo pharmacies. The new packaging is more colourful allowing it to stand out and Tata'sFossence® branding is moreprominent on pack. The Gofigure®products are made in India by local manufacturers and include ingredients such asTata's proprietaryFossence® which bring the assurance and familiarity of a branded ingredient from a well-known and respected local source to the attention of Indian consumers.

Stephen O'Hara, CEO of OptiBiotix, commented: *"Launching products on Amazon Indiais another step forward in building a presence for the Company's products in the strategically important Indian market. We are now building SlimBiome's® presence across India via our own brand products through Amazon India and via Apollo pharmacies, and as private label partnerships following the recent launch by Dr Morepen. This initial launch will include four products with subsequent launches taking place throughout 2025 dependent on sales progress."*

The Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman *Contact via Walbrook below*
Stephen O'Hara, Chief Executive

Peterhouse Capital Limited (Broker) Tel: 020 7220 9797
Duncan Vasey / Lucy Williams

Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy

About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUBVVRVAUAAAR